Antidiuretic Effects of a Novel Nonpeptide Vasopressin V 2-Receptor Agonist, OPC-51803, Administered Orally to Dogs

Journal of Pharmacological Sciences

Volumn 94, Issue 4, 2004, Pages 426-433

  Nakamura, Shigeki ^a   Hirano, Takahiro ^a   Onogawa, Toshiyuki ^a   Itoh, Shuji ^a   Hashimoto, Ayako ^a   Yamamura, Yoshitaka ^a   Kondo, Kazumi ^a   Mori, Toyoki ^a   Kambe, Toshimi ^a  

^a OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Antidiuresis; Nonpeptide; OPC 51803; V2 agonist

Indexed keywords

2 [1 [2 CHLORO 4 (1 PYRROLIDINYL)BENZOYL] 2,3,4,5 TETRAHYDRO 1H 1 BENZAZEPIN 5 YL] N ISOPROPYLACETAMIDE; ARGIPRESSIN; OPC 51803; UNCLASSIFIED DRUG; VASOPRESSIN DERIVATIVE; VASOPRESSIN V1 RECEPTOR; VASOPRESSIN V2 RECEPTOR; VASOPRESSIN V2 RECEPTOR AGONIST;

ANIMAL EXPERIMENT; ANTIDIURESIS; ARTICLE; CONTROLLED STUDY; DIURESIS; DOG; DOSE RESPONSE; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; KIDNEY BLOOD FLOW; MALE; NONHUMAN; PATHOPHYSIOLOGY; THROMBOCYTE MEMBRANE; URINE OSMOLALITY; URINE VOLUME;

EID: 2342511037     PISSN: 13478613     EISSN: None     Source Type: Journal    
DOI: 10.1254/jphs.94.426     Document Type: Article

References (34)

1. 2-receptor agonist, OPC-51803, administered orally to rats. J Pharmacol Exp Ther. 2000;295: 1005-1011.
2. 2-agonist, OPC-51803, in cells transfected human vasopressin receptor subtypes. Br J Pharmacol. 2000;129:1700-1706.
3. 2 receptor antagonists: a novel series of 1-[4-(benzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-benzazepines and related compounds. J Med Chem. 1996;39:3547-3555.
4. 2 receptor antagonist. Br J Pharmacol. 1992;105:787-791.
5. 2-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats. J Pharmacol Exp Ther. 2000;292:288-294.
6. 2 receptor antagonist. Bioorg Med Chem. 1999;7:1743-1754.
7. 2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther. 1998;287:860-867.
8. Albrightson-Winslow CR, Caldwell N, Brooks DP, Huffman WF, Stassen FL, Kinter LB. Cyclooxygenase inhibition unmasks the full antidiuretic agonist activity of the vasopressin antagonist, SK&F 101926, in dogs. J Pharmacol Exp Ther. 1989;249: 366-371.
9. Albrightson-Winslow CR, Brickson B, Brooks DP, et al. Vasopressin antidiuretic agonist and antagonist activity in dogs: structural and stereochemical relationship between bridge and carboxyl terminus. J Pharmacol Exp Ther. 1991;256:335-340.
10. Pettibone DJ, Kishel MT, Woyden CJ, et al. Radioligand binding studies reveal marked species differences in the vasopressin V1 receptor of rat, rhesus and human tissues. Life Sci. 1992;50: 1953-1958.
11. Shinoura H, Take H, Itoh S, et al. Key amino acids of vasopressin V1a receptor responsible for the species difference in the affinity of OPC-21268. FEBS Lett. 2000;466:255-258.
12. Durrieu G, Valet P, Berlan M, Villeneuve A, Montastruc JL. Levodopa up-regulates platelet alpha 2-adrenoceptors. Eur J Pharmacol. 1990;182:597-601.
13. 3H-spiroperidol binding sites in blood platelets. Biochem Biophys Res Commun. 1987;146:983-988.
14. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-254.
15. Scatchard G. The attractions of proteins for small molecules and ions. Ann NY Acad Sci. 1949;51:660-672.
16. 50) of an enzymatic reaction. Biochem Pharmacol. 1973;22:3099-3108.
17. Davidson WD, Sackner MA. Simplification of the anthrone method for the determination of inulin in clearance studies. J Lab Clin Med. 1963;62:351-356.
18. Stassen FL, Erickson RW, Huffman WF, Stefankiewicz J, Sulat L, Wiebelhaus VD. Molecular mechanisms of novel antidiuretic antagonists: analysis of the effects on vasopressin binding and adenylate cyclase activation in animal and human kidney. J Pharmacol Exp Ther. 1982;223:50-54.
19. Thibonnier M, Roberts JM. Characterization of human platelet vasopressin receptors. J Clin Invest. 1985;76:1857-1864.
20. Vilhardt H, Bie P. Antidiuretic response in conscious dogs following peroral administration of arginine vasopressin and its analogues. Eur J Pharmacol. 1983;93:201-204.
21. 2 vasopressin-receptor-mediated renal vasodilation. J Cardiovasc Pharmacol. 1994;23:331-336.
22. 2 receptors in conscious dogs. Am J Physiol. 1993;265:R934-R942.
23. Inoue T, Terris J, Ecelbarger CA, Chou CL, Nielsen S, Knepper MA. Vasopressin regulates apical targeting of aquaporin-2 but not of UT1 urea transporter in renal collecting duct. Am J Physiol. 1999;276:F559-F566.
24. Nielsen S, Knepper MA. Vasopressin activates collecting duct urea transporters and water channels by distinct physical processes. Am J Physiol. 1993;265:F204-F213.
25. Aikawa T, Kasahara T, Uchiyama M. Circadian variation of plasma arginine vasopressin concentration, or arginine vasopressin in enuresis. Scand J Urol Nephrol Suppl. 1999;202:47-49.
26. Asplund R, Aberg H. Diurnal variation in the levels of anti-diuretic hormone in the elderly. J Intern Med. 1991;229:131-134.
27. Devitt H, Holland P, Butler R, Redfern E, Hiley E, Roberts G. Plasma vasopressin and response to treatment in primary nocturnal enuresis. Arch Dis Child. 1999;80:448-451.
28. Lackgren G, Neveus T, Stenberg A. Diurnal plasma vasopressin and urinary output in adolescents with monosymptomatic nocturnal enuresis. Acta Paediatr. 1997;86:385-390.
29. Ouslander JG, Nasr SZ, Miller M, et al. Arginine vasopressin levels in nursing home residents with nighttime urinary incontinence. J Am Geriatr Soc. 1998;46:1274-1279.
30. Rittig S, Knudsen UB, Norgaard JP, Pedersen EB, Djurhuus JC. Abnormal diurnal rhythm of plasma vasopressin and urinary output in patients with enuresis. Am J Physiol. 1989;256:F664-F671.
31. Fjellestad-Paulsen A, Tubiana-Rufi N, Harris A, Czernichow P. Central diabetes insipidus in children. Antidiuretic effect and pharmacokinetics of intranasal and peroral 1-deamino-8-D-arginine vasopressin. Acta Endocrinol (Copenh). 1987;115:307-312.
32. Hammer M, Vilhardt H. Peroral treatment of diabetes insipidus with a polypeptide hormone analog, desmopressin. J Pharmacol Exp Ther. 1985;234:754-760.
33. Fjellestad-Paulsen A, Hoglund P, Lundin S, Paulsen O. Pharmacokinetics of 1-deamino-8-D-arginine vasopressin after various routes of administration in healthy volunteers. Clin Endocrinol (Oxf). 1993;38:177-182.
34. Vilhardt H, Lundin S. Biological effect and plasma concentrations of DDAVP after intranasal and peroral administration to humans. Gen Pharmacol. 1986;17:481-483.